Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.
Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S, Moskowitz CH. Matasar MJ, et al. Among authors: fayad l. Blood. 2013 Jul 25;122(4):499-506. doi: 10.1182/blood-2012-12-472027. Epub 2013 May 21. Blood. 2013. PMID: 23692856 Free PMC article. Clinical Trial.
Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.
Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F, Cox JD. Chronowski GM, et al. Among authors: fayad l. Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):36-43. doi: 10.1016/s0360-3016(02)03915-9. Int J Radiat Oncol Biol Phys. 2003. PMID: 12504034
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Dang NH, et al. Among authors: fayad l. J Clin Oncol. 2004 Oct 15;22(20):4095-102. doi: 10.1200/JCO.2004.03.071. Epub 2004 Sep 7. J Clin Oncol. 2004. PMID: 15353540 Clinical Trial.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Goy A, et al. Among authors: fayad l. J Clin Oncol. 2005 Feb 1;23(4):667-75. doi: 10.1200/JCO.2005.03.108. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613697 Clinical Trial.
Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Anderlini P, et al. Among authors: fayad l. Bone Marrow Transplant. 2005 May;35(10):943-51. doi: 10.1038/sj.bmt.1704942. Bone Marrow Transplant. 2005. PMID: 15806128
503 results